STAT+: They carry a gene for ALS but aren’t sick. What does medical research owe them?
Nine months after her mom died of ALS, Jean Swidler walked into a doctor’s office…
Category: STAT+
STAT+: What to know about the polarizing ALS drug headed for FDA scrutiny next week
Years of polarizing scientific discourse and bruising online debate will come to a head next…
STAT+: Hearing on Medicare drug price negotiation gets unusually heated
WASHINGTON — Republicans and Democrats fought it out over Medicare drug price negotiation Wednesday at…
STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions
For the fourth time this year, Novartis has been reprimanded by a U.K. trade group…
STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: AI is coming to your dentist’s office. Will it build trust, or erode it?
Open wide, AI wants a look inside your mouth. A new wave of software is…
STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind
Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved…
STAT+: How a cash-prize system that phases out patents may lower drug prices
Two months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he…
STAT+: FDA weighs animal data, ethical dilemmas at panel on artificial wombs
The Food and Drug Administration’s advisory panel of pediatric experts met on Tuesday to discuss…
STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism
WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of…
STAT+: Pear’s shadow effect: Data from a Medicaid digital health experiment does the policy rounds
Pear Therapeutics may be gone, but one of its most important deals is still driving…
STAT+: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Demand for new lab space has plummeted by more than half since the end of…
STAT+: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost
Following a high-profile pressure campaign, the company that makes a crucial tuberculosis test has agreed…
STAT+: Artificial wombs, after years in development, reach FDA review for human trials
The artificial womb, a device aiming to save infants born way too soon, is inching…
STAT+: Patients, doctors press FTC to beef up hospital merger scrutiny
Comments to antitrust regulators lay bare Americans’ anger and disillusionment over consolidation’s effects on all…
STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Medicare wants to increase payments for heart rehab. Hospitals see an opening to get more
Medicare plans to pay more for a type of cardiac rehabilitation that takes place in…
STAT+: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells
David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching…
STAT+: South Africa investigates Johnson & Johnson over ‘excessive pricing’ for its TB drug
South African authorities are investigating Johnson & Johnson and its Janssen subsidiary over “excessive pricing”…
STAT+: Chamber of Commerce, government clash at first court hearing on Medicare drug prices
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday…
STAT+: Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue
Boston isn’t the only city slated for a new cancer center. Far from it. There’s…
STAT+: Dana-Farber blindsided Brigham and Women’s. The blowback will be strong
This column is from Trendlines, a business newsletter that covers the forces shaping the economy…
STAT+: Pharmalittle: House panel inches into fixing drug shortages; pharma could face legal action over improper patent listings
And so, another working week will soon draw to a close. Not a moment too…
STAT+: House subcommittee forays into fixing drug shortages
WASHINGTON — A House subcommittee took a first step today toward legislation to fix drug…
STAT+: FTC warns drugmakers they can face legal action over improper patent filings
The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly…
New Senate deal would ban some facility fees, reform hospital contracting
WASHINGTON — A new, bipartisan deal in the Senate to fund primary care programs also…
STAT+: Medicare is urged to monitor how rebates affect Part D drug spending, but agency demurs
The U.S. government should monitor the effect that rebates have on Medicare Part D plans…
STAT+: Pharmalittle: White House imposes price limits for Regeneron Covid drug; lawmakers push federal agencies to prevent patent abuses
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Machine learning biotech raises $273 million in rare successful late-stage round
Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million…
STAT+: Civica Rx considers moving into chemo drugs as shortages worsen
WASHINGTON — A nonprofit formed by hospitals to deal with drug shortages is considering a…
Novelist John Green launches attack on Cepheid over the price of its TB test
John Green, a novelist and high-profile YouTuber, is once again leveraging his star power in…
STAT+: What to make of Biden’s latest cancer moonshot efforts
WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While…
STAT+: Lawmakers introduce bill to require drugmakers to provide key info to both FDA and U.S. Patent Office
Amid concerns over monopolies held by drugmakers, a bipartisan group of lawmakers introduced a bill…
STAT+: Pharmalittle: FDA panel says popular decongestant doesn’t work; U.S. warns companies over illegally marketed eye products
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Opinion: STAT+: The IRA needs changes to better support patients with rare diseases
This time last year, members of Congress were working around the clock to draft and…
STAT+: How Silicon Valley’s hospital whisperer bridges the gap between startups and health systems
SAN FRANCISCO — As part of one of the tech industry’s most revered venture funds,…
STAT+: White House touts efforts to stem cancer drug shortages
WASHINGTON — The White House says it’s working to end shortages of three key generic…
STAT+: Neurocrine Biosciences drug for congenital adrenal hyperplasia succeeds in late-stage trial
SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal…
STAT+: Walmart may buy concierge Medicare Advantage provider ChenMed. But will it scale?
Walmart seems poised to increase its health care footprint by buying value-based senior care company…
STAT+: Pharmalittle: Is Pascal Soriot leaving AstraZeneca? PBMs try to counter congressional crackdown
Hello, everyone, and nice to see you again after our extended break. A little time…
STAT+: Nick Leschly departs Bluebird Bio spinout amid restructuring, layoffs
Some two years after splitting biotech company Bluebird Bio into two entities in a bid…
.jpg)
STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to…
STAT+: Here are the dozens of weight loss drugs in development to catch a booming market
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit…
STAT+: Acelyrin, a rare IPO success, stumbles in its first big test
The biotech company Acelyrin, which raised more than $500 million in an IPO this year,…
STAT+: Pharmalittle: Biden’s NIH nominee will get a hearing; top Democrat backs bill to ban PBM spread pricing
Good morning, Jason Mast here filling in for Ed. Today, I’m drinking a cup of…
STAT+: Experts fear private equity will pour gas on cardiology’s overuse problem
Coronary stenting is, by some measures, the most overused procedure in hospitals. The problem costs…
STAT+: Crinetics acromegaly drug succeeds in late-stage trial but would face stiff competition if approved
SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a…
STAT+: House transparency, PBM reform bill gains bipartisan support
WASHINGTON — A Democrat has signed on to a legislative package that would require health…
STAT+: Pharmalittle: Novartis R&D hub’s name change reflects strategy shift; Lilly’s Mounjaro backed by U.K. watchdog
Good morning, Pharmalittle family! Adam Feuerstein here, filling in for Ed. My morning coffee was…